Tweet
Fiduciary Trust Co. trimmed its position in Abbott Laboratories (NYSE:ABT) by 1.9% during the second quarter, Holdings Channel reports. The institutional investor owned 371,610 shares of the healthcare product maker's stock after selling 7,329 shares during the period. Fiduciary Trust Co.'s holdings in Abbott Laboratories were worth $22,664,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently bought and sold shares of the company. TRUE Private Wealth Advisors lifted its holdings in Abbott Laboratories by 7.9% in the second quarter. TRUE Private Wealth Advisors now owns 11,546 shares of the healthcare product maker's stock valued at $704,000 after acquiring an additional 842 shares during the period. Altium Wealth Management LLC lifted its holdings in Abbott Laboratories by 18.7% in the first quarter. Altium Wealth Management LLC now owns 5,618 shares of the healthcare product maker's stock valued at $337,000 after acquiring an additional 886 shares during the period. Rehmann Capital Advisory Group lifted its holdings in Abbott Laboratories by 11.2% in the fourth quarter. Rehmann Capital Advisory Group now owns 8,886 shares of the healthcare product maker's stock valued at $507,000 after acquiring an additional 892 shares during the period. Tandem Investment Advisors Inc. lifted its holdings in Abbott Laboratories by 0.3% in the second quarter. Tandem Investment Advisors Inc. now owns 263,225 shares of the healthcare product maker's stock valued at $16,054,000 after acquiring an additional 897 shares during the period. Finally, Hills Bank & Trust Co. lifted its holdings in Abbott Laboratories by 3.8% in the second quarter. Hills Bank & Trust Co. now owns 24,513 shares of the healthcare product maker's stock valued at $1,495,000 after acquiring an additional 907 shares during the period. Hedge funds and other institutional investors own 71.80% of the company's stock. Get Abbott Laboratories alerts:
A number of equities research analysts have commented on the company. Royal Bank of Canada reissued a "buy" rating and issued a $70.00 target price on shares of Abbott Laboratories in a report on Thursday, July 19th. Stifel Nicolaus raised their target price on Abbott Laboratories from $71.00 to $72.00 and gave the company a "buy" rating in a report on Thursday, July 19th. Zacks Investment Research downgraded Abbott Laboratories from a "buy" rating to a "hold" rating in a report on Monday, August 6th. Sanford C. Bernstein initiated coverage on Abbott Laboratories in a research note on Wednesday, June 27th. They set an "outperform" rating and a $73.00 price target for the company. Finally, Citigroup cut their price target on Abbott Laboratories from $66.00 to $65.00 and set a "neutral" rating for the company in a research note on Tuesday, April 24th. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. The stock currently has a consensus rating of "Buy" and a consensus price target of $69.88. In related news, EVP Brian J. Blaser sold 15,100 shares of Abbott Laboratories stock in a transaction dated Tuesday, July 24th. The stock was sold at an average price of $63.96, for a total transaction of $965,796.00. Following the completion of the sale, the executive vice president now owns 151,718 shares in the company, valued at approximately $9,703,883.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . Also, insider Sharon J. Bracken sold 615 shares of Abbott Laboratories stock in a transaction dated Monday, July 30th. The stock was sold at an average price of $65.16, for a total value of $40,073.40. Following the sale, the insider now owns 40,761 shares of the company's stock, valued at approximately $2,655,986.76. The disclosure for this sale can be found here . In the last quarter, insiders have sold 17,024 shares of company stock valued at $1,088,840. 0.74% of the stock is currently owned by company insiders.
NYSE:ABT opened at $64.16 on Friday. The firm has a market cap of $112.33 billion, a PE ratio of 25.66, a PEG ratio of 1.79 and a beta of 1.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.58 and a quick ratio of 1.16. Abbott Laboratories has a 52-week low of $48.58 and a 52-week high of $65.90.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, July 18th. The healthcare product maker reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.02. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.71 billion. Abbott Laboratories had a return on equity of 15.30% and a net margin of 3.13%. The business's revenue was up 17.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.62 EPS. analysts expect that Abbott Laboratories will post 2.88 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 15th. Investors of record on Friday, July 13th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 1.75%. The ex-dividend date was Thursday, July 12th. Abbott Laboratories's dividend payout ratio is presently 44.80%.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; MÃ©niÃ¨re's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
See Also: Google Finance Portfolio
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT). Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter 